Bright Minds Biosciences : Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2023 and 2022 (Expressed in Canadian Dollars)

Bright Minds Biosciences Inc.


Condensed Interim Consolidated Financial Statements


For the three and nine months ended June 30, 2023 and 2022



...
-Today at 06:32 am- MarketScreener

Related Keywords

Vancouver ,British Columbia ,Canada ,United Kingdom ,United States ,Australia ,State Of California ,California ,New York ,Delaware ,British ,Australian ,Canadian ,Ian Mcdonald ,Karl Deisseroth ,Bright Minds Bioscience Pty Ltd ,Psilocybinlabs Ltd ,International Accounting Standard ,Bright Minds Biosciences Inc ,Board Of Directors The Company ,International Financial Reporting Standards ,Company See ,International Accounting Standards Board ,University Of Texas Medical Branch ,Pfws Of The Company ,Canadian Stock Exchange ,Company Vice ,Company On ,Board Of Trustees ,Units Of The Company ,Development Tax Incentive ,Directors Of The Company ,Bright Minds Biosciences ,University See ,Nasdaq ,Canadian Dollars ,Interim Consolidated Statements ,Condensed Interim Consolidated Financial ,Minds Biosciences ,Business Corporations Act ,Georgia Street ,Corporations Act ,Bright Minds Bioscience Pty ,Each Warrant ,Payment Shares ,New York Based ,National Policy ,Initial Public Offerings ,Chief Medical Officer ,Black Scholes ,Key Management ,Patent Rights ,Technical Information ,Net Sales ,Sublicensee Revenue ,Chief Science Officer ,Texas Medical Branch ,Vice President ,Wisconsin United States ,New York United States ,Right Of Use Assets ,Lease Liabilities ,Lease Liability Continuity ,Markets ,